WEBULL
WebtradeDownload

Kits Eyecare (TSX:KITS) Stock Can Profit Growth Justify An 87.1x P/E

Simply Wall St · 2d ago

Kits Eyecare stock came into this earnings print already on a strong run, with a 90 day gain of about 25% and the shares closing at CA$14.43 on 5 August. The market has been paying up for the story, with the stock on a rich trailing P/E of 87.1x. That makes today’s headline all about whether the margin picture can support that kind of valuation.

The immediate hook is simple. Q2 revenue reached CA$58.4 million while net profit margin sits near 2.5% on a trailing basis. The key issue for investors is whether this early profitability adequately reflects the price already embedded in the shares.

Love the revenue traction at Kits Eyecare but concerned about paying a high P/E for modest margins? Take a look at our curated list of 12 high quality undervalued stocks to see how this stock stacks up against peers with stronger earnings support.

Q2 2026 Earnings Summary

  • Revenue (Q2 2026 vs Q2 2025): CA$58.4 million vs. CA$49.6 million (up 17.8%)
  • Net Income (Q2 2026 vs Q2 2025): CA$1.5 million profit vs. CA$0.7 million loss (swing into profit)
  • Basic EPS (Q2 2026 vs Q2 2025): CA$0.043 vs. a loss of CA$0.022 per share (swing into profit per share)
  • Gross Margin (Q2 2026 vs Q2 2025): 37.9% vs. 36.3% (up 1.6 percentage points)

Prefer clear visuals instead of another wall of earnings tables and raw figures? See Kits Eyecare’s full financial picture, including how the current P/E compares with recent profitability, in our company report for Kits Eyecare.

TSX:KITS Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026
TSX:KITS Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026

Kits Eyecare results backing a cautious bull view

The latest quarter gives bulls in Kits Eyecare some real numbers to point to. Revenue grew 17.8% year on year and glasses are scaling quickly, with category revenue up 54% and now close to a fifth of sales. Profitability moved in the right direction, from a loss to a CA$1.5 million profit, with gross margin at 37.9% and adjusted EBITDA positive for the 15th straight quarter. Cash generation looks healthy, with record operating cash flow and no debt, which supports the idea of a self funded growth story.

Profit trade offs keep the bearish case alive

The cautious view on Kits Eyecare still has fuel. Management is leaning into higher cost glasses acquisition, which lifted marketing to 17.4% of revenue and keeps adjusted EBITDA margin in the mid single digits. Fulfillment expenses face pressure from fuel surcharges that the company is currently absorbing. There is also execution risk as the retail footprint expands and marketing shifts back toward contacts in the second half of 2026. The business is profitable and liquid today, yet the path to structurally higher margins is not proven.

After rising marketing costs, heavier glasses investment and expanding retail, are these trade offs masking deeper structural issues? Review our risk analysis for Kits Eyecare which shows 1 important warning sign

Take Control Of Your Next Move

If Kits Eyecare’s shift into profitability and higher marketing spend has your attention, register for free with Simply Wall St and add it to your Watchlist to track share price against fair value and watch how margins evolve before deciding on an entry point. Once you own Kits Eyecare or any other stock, use the Portfolio Command Center to cut through noise and focus on the updates that matter to your holdings. For a broader view on sentiment and potential blind spots, tap into the Community and see how other investors are thinking about opportunities and risks. This combination helps you spot hidden catalysts and potential warning signs early so you can stay ahead of the market.

Seeking Alternatives Before The Window Closes

Some stocks are building quiet breakout momentum while others are dropping from the radar. Get to fresh ideas before the crowd and act while it still matters. Act now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.